Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome.
104317
Phase 3 other active
Quick answer
Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome. for Hypereosinophilic Syndrome is a Phase 3 program (other) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline Biologicals S.A.
- Indication
- Hypereosinophilic Syndrome
- Phase
- Phase 3
- Modality
- other
- Status
- active